New immune cell therapy shows promise in early cancer trial
NCT ID NCT03096093
First seen Jan 29, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This early-phase study tests a new cell therapy called ACIT-1 in adults with pancreatic or other cancers. The goal is to find the safest dose that can boost the body's immune system to fight cancer. About 34 people will take part, and researchers will monitor side effects and survival time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Royal Liverpool University Hospital
Liverpool, Merseyside, L7 8XP, United Kingdom
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Wirral, CH63 4JY, United Kingdom
Conditions
Explore the condition pages connected to this study.